Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 9, 2008, Pages 1128-1136

  Tsochatzis, Emmanuel ^a   Papatheodoridis, George V ^a   Hadziyannis, Emilia ^a   Georgiou, Anastasia ^a   Kafiri, Georgia ^b   Tiniakos, Dina G ^a   Manesis, Emanuel K ^a   Archimandritis, Athanasios J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Adipokines; Adiponectin; Chronic hepatitis B; Chronic hepatitis C; Leptin; Non alcoholic steatohepatitis; Resistin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; RESISTIN;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; GENDER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ADIPOKINES; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CHRONIC DISEASE; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROBABILITY; PROGNOSIS; PROSPECTIVE STUDIES; RESISTIN; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 49949085308     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802085387     Document Type: Article

References (33)

1. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;8:671-80.
2. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006;11:2629-40.
3. McTernan PG, Kusminski CM, Kumar S. Resistin. Curr Opin Lipidol 2006;2:170-5.
4. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;5:987-1000.
5. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Digest Liver Dis 2007;39:936-42.
6. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol 2007;3:634-41.
7. Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:1154-61.
8. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006;6:1244-52.
9. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;19:2486-97.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;7:412-9.
11. Ishak K, Baptista A, Bianchi L, Callea F, De GJ, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;6:696-9.
12. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;9:2467-74.
13. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de IR, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005;6:3498-504.
14. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;2:403-9.
15. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005;6:929-36.
16. Liu CJ, Chen PJ, Jeng YM, Huang WL, Yang WS, Lai MY, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol 2005;2:235-42.
17. Hui C, Zhang H, Lee N, Chan W, Yueng Y, Leung K, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol 2007;47:191-202.
18. Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis A, Makri M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007;14:577-83.
19. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;6:943-9.
20. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;1:46-54.
21. Crespo J, Rivero M, Fabrega E, Cayon A, Amado JA, Garcia-Unzeta MT, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;7:1604-10.
22. Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000;11:3211-7.
23. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;4:842-5.
24. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005;7:1003-8.
25. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 2005;1:41-6.
26. Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005;12:2717-23.
27. Lo Iacono O, Venezia G, Petta S, Mineo C, De LS, Di MV, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007;10:1181-91.
28. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol 2006;169:2042-53.
29. Tietge UJ, Boker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004;1:E82-9.
30. Sato S, Furuta K, Mishiro T, Miyake T, Kohge N, Akagi S, et al. Serum adiponectin concentration in patients with hepatitis C virus. J Clin Gastroenterol 2005;8:744-5.
31. Piche T, Vandenbos F, Bakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepatol 2004;1:91-6.
32. Romero-Gomez M, Castellano-Megias VM, Grande L, Irles JA, Cruz M, Nogales MC, et al. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003;5:1135-41.
33. Manolakopoulos S, Bethanis S, Liapi C, Stripeli F, Sklavos P, Margeli A, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study. BMC Gastroenterol 2007;1:17.